Mostrar el registro sencillo del ítem
Artículo
Association Between Drug Burden Index and Functional and Cognitive Function in Patients with Multimorbidity
dc.creator | Villalba-Moreno, Angela Ma | es |
dc.creator | Alfaro Lara, Eva Rocío | es |
dc.creator | Rodríguez-Pérez, Aitana | es |
dc.creator | Báñez Toro, Daniel | es |
dc.creator | Sánchez Fidalgo, Susana | es |
dc.creator | Pérez Guerrero, María Concepción | es |
dc.creator | Santos-Ramos, Bernardo | es |
dc.creator | Nieto Martín, María Dolores | es |
dc.date.accessioned | 2024-02-29T14:48:44Z | |
dc.date.available | 2024-02-29T14:48:44Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Villalba-Moreno, A.M., Alfaro Lara, E.R., Rodríguez-Pérez, A., Báñez Toro, D., Sánchez Fidalgo, S., Pérez Guerrero, M.C.,...,Nieto Martín, M.D. (2018). Association Between Drug Burden Index and Functional and Cognitive Function in Patients with Multimorbidity. Current Pharmaceutical Design, 24 (28), 3384-3391. https://doi.org/10.2174/1381612824666180327154239. | |
dc.identifier.issn | 1381-6128 | es |
dc.identifier.issn | 1873-4286 | es |
dc.identifier.uri | https://hdl.handle.net/11441/155703 | |
dc.description.abstract | Background: Anticholinergic and sedative drugs are associated with adverse events such as cognitive and functional impairment in elderly. The Drug Burden Index (DBI) is a measure of an individual’s total exposure to anticholinergic and sedative drugs. Objetive: The study aimed to evaluate the association between the total DBI and cognitive and functional impairment in patients with multimorbidity. Setting: Patients with multimorbidity enrolled in the IMPACTO project. Methods: Cross-sectional observational study. Main outcome measure: The anticholinergic and sedative exposure was calculated using DBI. The Pfeiffer Test (PT) was used for cognitive status and the Barthel Index (BI) for functional status. Results: 336 patients were included (mean age 77.6 ± 8.7 years, 54.2% men and a mean of 11.5 ± 3.7 prescribed drugs). 180 patients (53.6%) exposed to anticholinergic and/or sedative drugs were identified. The median score obtained in PT was slightly higher in exposed patients (1 (IQR 0-2) and 2 (IQR 0-4), p = 0.082 in "non-exposed" and "exposed", respectively). The bivariate analysis showed an association [0.544 (95% CI 0.044-1.063, p = 0.03)]. The median obtained in the BI analysis was 85.0 (IQR 30.0) and 75.5 (IQR 42.5) p = 0.002, in "nonexposed" and "exposed", respectively. After the adjusted analysis, a relationship was obtained between both the variables [-9,558 (95% CI-15,794; -3,321, p = 0.03)]. Conclusion: Higher DBI is associated with the impairment of functional status and, slightly to the deterioration of cognitive function in patients with multimorbidity. DBI should be considered in patients with multimorbidity to optimize the pharmacological treatment of a group of special interest due to its vulnerability. | es |
dc.format | application/pdf | es |
dc.format.extent | 8 p. | es |
dc.language.iso | eng | es |
dc.publisher | Bentham Science Publishers | es |
dc.relation.ispartof | Current Pharmaceutical Design, 24 (28), 3384-3391. | |
dc.subject | Anticholinergic burden | es |
dc.subject | Anticholinergic drugs | es |
dc.subject | Drug burden index | es |
dc.subject | Frail elderly | es |
dc.subject | Multimorbidity | es |
dc.subject | Pfeiffer test | es |
dc.title | Association Between Drug Burden Index and Functional and Cognitive Function in Patients with Multimorbidity | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/acceptedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/embargoedAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina Preventiva y Salud Pública | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.date.embargoEndDate | 2019 | |
dc.relation.publisherversion | https://www.eurekaselect.com/article/89339 | es |
dc.identifier.doi | 10.2174/1381612824666180327154239 | es |
dc.journaltitle | Current Pharmaceutical Design | es |
dc.publication.volumen | 24 | es |
dc.publication.issue | 28 | es |
dc.publication.initialPage | 3384 | es |
dc.publication.endPage | 3391 | es |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Aceptada Association Between ... | 277.5Kb | ![]() | Ver/ | |
Este registro aparece en las siguientes colecciones
Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.